Arno Licenses Technology from U of Minnesota for CDx Development | GenomeWeb

NEW YORK (GenomeWeb News) – Arno Therapeutics today announced it has inked an exclusive, worldwide licensing deal with the University of Minnesota for a technology covering a gene expression signature derived from archived breast cancer tissue samples.

As part of the deal, Arno will continue development of a progesterone receptor gene signature as a potential companion diagnostic for anti-progestins, including Arno's lead compound called onapristone for treating men's and women's cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.